MALAT1 and plasma cell myeloma: In multiple myeloma xenografts, MALAT1 LNA-gapmeR or nanotube-delivered anti-MALAT1 oligos trigger apoptosis and impair tumor growth, demonstrating nuclear target engagement and therapeutic effect in vivo [458, 459].